The abstract is read at the publisher; the summary is JClub's.
A cell-free microfluidics platform quantified 31,740 affinities for 518 SARS-CoV-2 RBD triplet mutants, generating three binding energy landscapes against two therapeutic antibodies and one engineered binder.
- Why it matters: Ongoing SARS-CoV-2 evolution requires mapping how RBD mutations and their combinations affect antibody evasion, including cumulative and epistatic effects.
- What they did: The study used rapid in vitro gene assembly with cell-free protein synthesis and microfluidics to express 518 RBD variants and measure quantitative binding affinities.
- The result: The resulting binding energy landscapes enable rapid, large-scale in vitro affinity profiling and machine-learning-based predictions for emerging variants.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.